Trials / Terminated
TerminatedNCT05367661
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CHK-336 in Healthy Volunteers
A Phase 1, Single-Center, Randomized, Placebo-Controlled, Double-Blind, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CHK-336 in Healthy Volunteers
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 88 (actual)
- Sponsor
- Chinook Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This study is designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamic effects of an investigational drug (CHK-336) when administered to healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CHK336 | Tablet |
| DRUG | Placebo | Tablet |
Timeline
- Start date
- 2022-04-08
- Primary completion
- 2023-04-19
- Completion
- 2023-04-19
- First posted
- 2022-05-10
- Last updated
- 2023-11-03
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05367661. Inclusion in this directory is not an endorsement.